MX2022009099A - Sars-cov-2 desoptimizados y metodos y usos de los mismos. - Google Patents
Sars-cov-2 desoptimizados y metodos y usos de los mismos.Info
- Publication number
- MX2022009099A MX2022009099A MX2022009099A MX2022009099A MX2022009099A MX 2022009099 A MX2022009099 A MX 2022009099A MX 2022009099 A MX2022009099 A MX 2022009099A MX 2022009099 A MX2022009099 A MX 2022009099A MX 2022009099 A MX2022009099 A MX 2022009099A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- sars
- deoptimized
- methods
- coronavirus infection
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 5
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 3
- 108020004705 Codon Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966750P | 2020-01-28 | 2020-01-28 | |
| US202063048942P | 2020-07-07 | 2020-07-07 | |
| US202063079337P | 2020-09-16 | 2020-09-16 | |
| US202063079853P | 2020-09-17 | 2020-09-17 | |
| PCT/US2021/015246 WO2021154828A1 (en) | 2020-01-28 | 2021-01-27 | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009099A true MX2022009099A (es) | 2022-10-20 |
Family
ID=77078567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009099A MX2022009099A (es) | 2020-01-28 | 2021-01-27 | Sars-cov-2 desoptimizados y metodos y usos de los mismos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230117167A1 (enExample) |
| EP (1) | EP4096712A4 (enExample) |
| JP (1) | JP2023519640A (enExample) |
| KR (1) | KR20220132588A (enExample) |
| CN (1) | CN115427073A (enExample) |
| AU (1) | AU2021213121A1 (enExample) |
| BR (1) | BR112022014700A2 (enExample) |
| CA (1) | CA3168100A1 (enExample) |
| CL (1) | CL2022002030A1 (enExample) |
| CO (1) | CO2022010743A2 (enExample) |
| IL (1) | IL295112A (enExample) |
| MX (1) | MX2022009099A (enExample) |
| PE (1) | PE20230166A1 (enExample) |
| PH (1) | PH12022551788A1 (enExample) |
| SA (1) | SA522433428B1 (enExample) |
| TW (1) | TW202144570A (enExample) |
| WO (1) | WO2021154828A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| MX2022009688A (es) * | 2020-02-07 | 2022-12-15 | Rnaimmune Inc | Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus. |
| WO2021177773A2 (ko) * | 2020-03-06 | 2021-09-10 | (주)지노믹트리 | Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법 |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2022011428A1 (en) * | 2020-07-16 | 2022-01-20 | Griffith University | Live-attenuated virus vaccine |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| TW202328166A (zh) | 2021-08-11 | 2023-07-16 | 美商達冕生物有限公司 | 針對新型冠狀病毒感染之ｍＲＮＡ疫苗之組成物及方法 |
| CN115704013A (zh) * | 2021-08-13 | 2023-02-17 | 北京化工大学 | 一种冠状病毒致弱突变株及其制备方法和应用 |
| US20250057939A1 (en) | 2021-09-08 | 2025-02-20 | Serum Institute Of India Private Limited | Freeze-dried viral combination vaccine compositions and process for preparation thereof |
| US20250295756A1 (en) * | 2022-01-20 | 2025-09-25 | Freie Universität Berlin | Live attenuated sars-cov-2 and a vaccine made thereof |
| KR20240163164A (ko) * | 2022-03-28 | 2024-11-18 | 유니버시태트 베른 | 원-투-스톱(One-to-stop) 약독화된 SARS-CoV-2 바이러스 |
| KR20250060275A (ko) | 2022-09-05 | 2025-05-07 | 프라이 유니베르시탯 베를린 | 살아있는 약독화된 SARS-CoV-2 및 이의 제조 백신 |
| EP4331602A1 (en) * | 2022-09-05 | 2024-03-06 | Freie Universität Berlin | A live attenuated sars-cov-2 and a vaccine made thereof |
| JP2025534031A (ja) * | 2022-10-12 | 2025-10-09 | ウニヴェルズィテート ベルン | ワントゥーストップ（ｏｎｅ－ｔｏ－ｓｔｏｐ）弱毒化ＳＡＲＳ－ＣｏＶ－２ウイルスによる治療 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024097259A1 (en) | 2022-11-01 | 2024-05-10 | RNAimmune, Inc. | Composition and methods for mrna vaccines against novel omicron coronavirus infections |
| WO2025081050A1 (en) * | 2023-10-13 | 2025-04-17 | Duke University | Coronavirus stem helix and fusion peptide nanoparticle vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7339051B2 (en) * | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
| EP2808384B1 (en) * | 2004-10-08 | 2017-12-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
| PL2139515T5 (pl) * | 2007-03-30 | 2024-04-08 | The Research Foundation Of The State University Of New York | Atenuowane wirusy przydatne w szczepionkach |
| US20120269849A1 (en) * | 2009-10-09 | 2012-10-25 | Eckard Wimmer | Attenuated influenza viruses and vaccines |
| CN104072592B (zh) * | 2013-03-26 | 2016-12-28 | 复旦大学 | 对新型冠状病毒HCoV-EMC 2012感染具有抑制作用的多肽及其应用 |
| KR20180085802A (ko) * | 2015-12-11 | 2018-07-27 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Ns1 및 ns2 유전자 이동을 포함하는 재조합 rsv 균주 |
| CN110506060B (zh) * | 2017-03-30 | 2024-05-07 | 昆士兰大学 | 嵌合分子及其用途 |
| US20200299651A1 (en) * | 2017-10-16 | 2020-09-24 | Glaxosmithkline Biologicals Sa | Simian adenoviral vectors with two expression cassettes |
-
2021
- 2021-01-27 CN CN202180024216.XA patent/CN115427073A/zh active Pending
- 2021-01-27 WO PCT/US2021/015246 patent/WO2021154828A1/en not_active Ceased
- 2021-01-27 EP EP21747780.1A patent/EP4096712A4/en active Pending
- 2021-01-27 AU AU2021213121A patent/AU2021213121A1/en not_active Abandoned
- 2021-01-27 CA CA3168100A patent/CA3168100A1/en active Pending
- 2021-01-27 IL IL295112A patent/IL295112A/en unknown
- 2021-01-27 BR BR112022014700A patent/BR112022014700A2/pt unknown
- 2021-01-27 KR KR1020227029265A patent/KR20220132588A/ko active Pending
- 2021-01-27 PH PH1/2022/551788A patent/PH12022551788A1/en unknown
- 2021-01-27 TW TW110103098A patent/TW202144570A/zh unknown
- 2021-01-27 MX MX2022009099A patent/MX2022009099A/es unknown
- 2021-01-27 US US17/794,862 patent/US20230117167A1/en active Pending
- 2021-01-27 PE PE2022001498A patent/PE20230166A1/es unknown
- 2021-01-27 JP JP2022572258A patent/JP2023519640A/ja active Pending
-
2022
- 2022-07-27 SA SA522433428A patent/SA522433428B1/ar unknown
- 2022-07-28 CL CL2022002030A patent/CL2022002030A1/es unknown
- 2022-07-29 CO CONC2022/0010743A patent/CO2022010743A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022002030A1 (es) | 2023-03-10 |
| PH12022551788A1 (en) | 2024-02-26 |
| US20230117167A1 (en) | 2023-04-20 |
| CO2022010743A2 (es) | 2022-08-30 |
| CA3168100A1 (en) | 2021-08-05 |
| EP4096712A4 (en) | 2024-05-08 |
| SA522433428B1 (ar) | 2024-10-08 |
| CN115427073A (zh) | 2022-12-02 |
| PE20230166A1 (es) | 2023-02-01 |
| JP2023519640A (ja) | 2023-05-11 |
| WO2021154828A1 (en) | 2021-08-05 |
| EP4096712A1 (en) | 2022-12-07 |
| AU2021213121A1 (en) | 2022-08-18 |
| TW202144570A (zh) | 2021-12-01 |
| BR112022014700A2 (pt) | 2022-10-11 |
| KR20220132588A (ko) | 2022-09-30 |
| IL295112A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551788A1 (en) | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF | |
| WO2021188969A3 (en) | Coronavirus vaccines and methods of use | |
| WO2022155530A8 (en) | Variant strain-based coronavirus vaccines | |
| WO2022221440A8 (en) | Influenza-coronavirus combination vaccines | |
| MX2022012576A (es) | Inhibidores de axl para terapia antiviral. | |
| WO2021178714A3 (en) | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | |
| WO2022015573A3 (en) | Sars-cov-2 antigen-binding proteins and uses thereof | |
| MX2024000304A (es) | Variantes desoptimizadas de sars-cov-2 y metodos y usos de las mismas. | |
| WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
| WO2022226423A3 (en) | Therapeutic interfering particles for corona virus | |
| WO2022119858A8 (en) | Compounds for the treatment of sars | |
| CA3179819A1 (en) | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments | |
| MX2022002174A (es) | Composicion de te con eficacia para prevenir o mejorar enfermedades respiratorias, y composicion farmaceutica que comprende la misma. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| WO2021198769A8 (en) | Vaccine compositions for the treatment of coronavirus | |
| WO2021257770A3 (en) | Sars-cov-2 immunodominant peptides and uses thereof | |
| MX2023014940A (es) | Bacteriofagos contra enterococci resistentes a la vancomicina. | |
| WO2022109317A9 (en) | Anti-influenza antibodies and combinations thereof | |
| PH12022550240A1 (en) | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof | |
| MX2021013609A (es) | Materiales y métodos para tratar la degeneración macular relacionada con la edad. | |
| WO2021202317A3 (en) | Novel methods of using nitric oxide donor compounds for treatment of covid-19 and other infectious diseases | |
| MX2023014984A (es) | Anticuerpos anti-csp. | |
| EP4545971A3 (en) | Peptide with neutralizing activity against severe acute respiratory syndrome coronavirus 2 | |
| WO2021211921A3 (en) | Methods of reducing or preventing clostridioides difficile colonization | |
| WO2021252896A3 (en) | Methods and compositions for treating coronavirus infectious disease |